Nearly a year ago, thirteen-year-old Liam Canard, of Raleigh, was diagnosed with Hodgkin’s lymphoma. Although his fight against the disease goes on today, he has already won by continuing to do what he loves.
A University of North Carolina at Chapel Hill analysis published today in the journal Tobacco Control synthesized the results of 37 different experiments comparing picture-based and text warnings, finding that picture-based warnings were more effective than text warnings on 20 of 25 different outcome measures.
A new treatment for melanoma could be on the horizon, thanks to a finding by a UNC Lineberger Comprehensive Cancer Center-led team. In the study, which was published online today in the journal Clinical Cancer Research, the authors report that they found high levels of an enzyme in melanoma samples that they believe is a potential drug target.
The new experimental assay can help scientists find the precise locations of repair of DNA damage caused by UV radiation and common chemotherapies. The invention could lead to better cancer drugs or improvements in the potency of existing ones.
A cancer genomics study led by UNC Lineberger researchers and other scientists involved in The Cancer Genome Atlas (TCGA) project, a National Cancer Institute and National Human Genome Research Institute-backed effort to create a comprehensive atlas of the genetic changes in cancer, was selected as one of the top 10 clinical research achievements of the year.
Fifteen years ago, Nancy Raasch was diagnosed with metastatic breast cancer. Then, in 2009, came multiple myeloma. Despite these malignancies, she refuses to let cancer define her.
A UNC Lineberger-led study found that people with higher-risk melanoma containing either BRAF or NRAS gene mutations had lower survival rates.
Using human cancer cell lines, UNC scientists identified various ways that HER2-positive breast cancer tumors resist therapy, and they discovered a potential combination therapy to overcome multiple mechanisms of resistance and kill cancer cells.
Two years ago, Carmen Ward was diagnosed with a type of breast cancer called mucinous carcinoma. In her early 80s, she continues to be grateful for the life she's led and the future she has, and she points to her care at UNC Hospitals for helping her maintain a positive outlook.
UNC sequenced the RNA for 10,000 tumor samples as part of The Cancer Genome Atlas project, a National Cancer Institute and National Human Genome Research Institute backed effort to create a comprehensive atlas of the genetic changes in cancer.
Two new faculty members have joined the UNC Lineberger Comprehensive Cancer Center to help launch groundbreaking immunotherapy clinical trials that will test an experimental treatment in which patients’ own immune cells are genetically engineered to fight their cancer.
Chuck Perou, PhD, professor of Genetics and Pathology at UNC Lineberger Comprehensive Cancer Center, was recently interviewed by Oncology Times for the publication's "Three Questions" series.
While studies have shown that the colonoscopy can reduce the risk of death from colorectal cancer, researchers have also shown that not all people recommended for the test actually get it.
A study led by a UNC Lineberger Comprehensive Cancer Center researcher has found that, despite a North Carolina law banning their purchase by minors and requiring online vendors to verify customer age, teens can easily buy electronic cigarettes online.
Hepatitis C virus infection is a common cause of liver disease and of liver cancer in the United States. Through a new study that explores one aspect of how the virus hijacks host cell machinery to replicate itself, UNC Lineberger Comprehensive Cancer Center researchers have gained insight into the workings of a potential drug target for hepatitis C.
The latest installment in our Real Medicine video series features one of our Patient Ambassadors for North Carolina Children's Hospital.
Scientists from UNC-Chapel Hill have created a new way to investigate epigenetic mechanisms important in diseases ranging from Alzheimer’s to cancers.
Device that drives drugs into solid tumors that are poorly vascularized opens the possibility of life-saving surgeries in cancer patients. James Byrne, PhD, a medical student and member of Joseph DeSimone’s lab, led the research by constructing the device and examining its ability to deliver chemotherapeutic drugs effectively to pancreatic cancer tumors, as well as two types of breast cancer tumors.
A study co-led by a UNC Lineberger Comprehensive Cancer Center researcher has identified genomic changes in head and neck cancers linked to the sexually transmitted disease HPV -- the latest finding of a collaborative scientific effort designed to map out the genomic changes driving cancer.
UNC geneticists led by Terry Magnuson, PhD, and Ron Chandler, PhD, create the first mouse model of ovarian clear cell carcinoma; show how a known drug can suppress tumor growth.